579 related articles for article (PubMed ID: 25209314)
1. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.
Han L; Li Y; Tchao J; Kaplan AD; Lin B; Li Y; Mich-Basso J; Lis A; Hassan N; London B; Bett GC; Tobita K; Rasmusson RL; Yang L
Cardiovasc Res; 2014 Nov; 104(2):258-69. PubMed ID: 25209314
[TBL] [Abstract][Full Text] [Related]
2. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
[TBL] [Abstract][Full Text] [Related]
3. Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation.
Guo G; Wang L; Li X; Fu W; Cao J; Zhang J; Liu Y; Liu M; Wang M; Zhao G; Zhao X; Zhou Y; Niu S; Liu G; Zhang Y; Dong J; Tao H; Zhao X
Cell Calcium; 2024 Jan; 117():102822. PubMed ID: 38101154
[TBL] [Abstract][Full Text] [Related]
4. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells.
Lan F; Lee AS; Liang P; Sanchez-Freire V; Nguyen PK; Wang L; Han L; Yen M; Wang Y; Sun N; Abilez OJ; Hu S; Ebert AD; Navarrete EG; Simmons CS; Wheeler M; Pruitt B; Lewis R; Yamaguchi Y; Ashley EA; Bers DM; Robbins RC; Longaker MT; Wu JC
Cell Stem Cell; 2013 Jan; 12(1):101-13. PubMed ID: 23290139
[TBL] [Abstract][Full Text] [Related]
5. Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with MYL2-R58Q-Mediated Apical Hypertrophic Cardiomyopathy Show Hypertrophy, Myofibrillar Disarray, and Calcium Perturbations.
Zhou W; Bos JM; Ye D; Tester DJ; Hrstka S; Maleszewski JJ; Ommen SR; Nishimura RA; Schaff HV; Kim CS; Ackerman MJ
J Cardiovasc Transl Res; 2019 Oct; 12(5):394-403. PubMed ID: 30796699
[TBL] [Abstract][Full Text] [Related]
6. Myosin inhibitor reverses hypertrophic cardiomyopathy in genotypically diverse pediatric iPSC-cardiomyocytes to mirror variant correction.
Kinnear C; Said A; Meng G; Zhao Y; Wang EY; Rafatian N; Parmar N; Wei W; Billia F; Simmons CA; Radisic M; Ellis J; Mital S
Cell Rep Med; 2024 May; 5(5):101520. PubMed ID: 38642550
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
[TBL] [Abstract][Full Text] [Related]
8. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.
Tanaka A; Yuasa S; Mearini G; Egashira T; Seki T; Kodaira M; Kusumoto D; Kuroda Y; Okata S; Suzuki T; Inohara T; Arimura T; Makino S; Kimura K; Kimura A; Furukawa T; Carrier L; Node K; Fukuda K
J Am Heart Assoc; 2014 Nov; 3(6):e001263. PubMed ID: 25389285
[TBL] [Abstract][Full Text] [Related]
9. Severe DCM phenotype of patient harboring RBM20 mutation S635A can be modeled by patient-specific induced pluripotent stem cell-derived cardiomyocytes.
Streckfuss-Bömeke K; Tiburcy M; Fomin A; Luo X; Li W; Fischer C; Özcelik C; Perrot A; Sossalla S; Haas J; Vidal RO; Rebs S; Khadjeh S; Meder B; Bonn S; Linke WA; Zimmermann WH; Hasenfuss G; Guan K
J Mol Cell Cardiol; 2017 Dec; 113():9-21. PubMed ID: 28941705
[TBL] [Abstract][Full Text] [Related]
10. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.
Toepfer CN; Garfinkel AC; Venturini G; Wakimoto H; Repetti G; Alamo L; Sharma A; Agarwal R; Ewoldt JK; Cloonan P; Letendre J; Lun M; Olivotto I; Colan S; Ashley E; Jacoby D; Michels M; Redwood CS; Watkins HC; Day SM; Staples JF; Padrón R; Chopra A; Ho CY; Chen CS; Pereira AC; Seidman JG; Seidman CE
Circulation; 2020 Mar; 141(10):828-842. PubMed ID: 31983222
[TBL] [Abstract][Full Text] [Related]
11. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
[TBL] [Abstract][Full Text] [Related]
12. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
[TBL] [Abstract][Full Text] [Related]
13. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
[TBL] [Abstract][Full Text] [Related]
14. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy.
Witjas-Paalberends ER; Piroddi N; Stam K; van Dijk SJ; Oliviera VS; Ferrara C; Scellini B; Hazebroek M; ten Cate FJ; van Slegtenhorst M; dos Remedios C; Niessen HW; Tesi C; Stienen GJ; Heymans S; Michels M; Poggesi C; van der Velden J
Cardiovasc Res; 2013 Aug; 99(3):432-41. PubMed ID: 23674513
[TBL] [Abstract][Full Text] [Related]
15. Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome.
Guo F; Sun Y; Wang X; Wang H; Wang J; Gong T; Chen X; Zhang P; Su L; Fu G; Su J; Yang S; Lai R; Jiang C; Liang P
Circ Res; 2019 Jan; 124(1):66-78. PubMed ID: 30582453
[TBL] [Abstract][Full Text] [Related]
16. Generation of two iPSC clones (MHHi021-A and MHHi021-B) from a patient with hypertrophic cardiomyopathy with p.Arg723Gly mutation in the MYH7 gene.
Merkert S; Wunderlich S; Beier J; Franke A; Schwanke K; Göhring G; Kraft T; Francino A; Zweigerdt R; Martin U
Stem Cell Res; 2021 Apr; 52():102208. PubMed ID: 33578365
[TBL] [Abstract][Full Text] [Related]
17. Silencing of
Dainis A; Zaleta-Rivera K; Ribeiro A; Chang ACH; Shang C; Lan F; Burridge PW; Liu WR; Wu JC; Chang ACY; Pruitt BL; Wheeler M; Ashley E
Physiol Genomics; 2020 Jul; 52(7):293-303. PubMed ID: 32567507
[TBL] [Abstract][Full Text] [Related]
18. Investigating the cardiac pathology of SCO2-mediated hypertrophic cardiomyopathy using patients induced pluripotent stem cell-derived cardiomyocytes.
Hallas T; Eisen B; Shemer Y; Ben Jehuda R; Mekies LN; Naor S; Schick R; Eliyahu S; Reiter I; Vlodavsky E; Katz YS; Õunap K; Lorber A; Rodenburg R; Mandel H; Gherghiceanu M; Binah O
J Cell Mol Med; 2018 Feb; 22(2):913-925. PubMed ID: 29193756
[TBL] [Abstract][Full Text] [Related]
19. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
[TBL] [Abstract][Full Text] [Related]
20. CRISPR correction of the PRKAG2 gene mutation in the patient's induced pluripotent stem cell-derived cardiomyocytes eliminates electrophysiological and structural abnormalities.
Ben Jehuda R; Eisen B; Shemer Y; Mekies LN; Szantai A; Reiter I; Cui H; Guan K; Haron-Khun S; Freimark D; Sperling SR; Gherghiceanu M; Arad M; Binah O
Heart Rhythm; 2018 Feb; 15(2):267-276. PubMed ID: 28917552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
